Idorsia and Viatris enter into a significant global research and development collaboration
28 févr. 2024 01h00 HE
|
Idorsia Pharmaceuticals Ltd
Ad hoc announcement pursuant to Art. 53 LR Viatris and Idorsia will collaborate on the global development and commercialization of two Phase 3 assets, selatogrel and cenerimod.Idorsia to receive an...
Idorsia and Viatris enter into a significant global research and development collaboration
28 févr. 2024 01h00 HE
|
Idorsia Pharmaceuticals Ltd
Ad hoc announcement pursuant to Art. 53 LR Viatris and Idorsia will collaborate on the global development and commercialization of two Phase 3 assets, selatogrel and cenerimod.Idorsia to receive an...
Idorsia presents at the J.P. Morgan Healthcare Conference – Adapting Idorsia for sustainable value creation
10 janv. 2024 01h00 HE
|
Idorsia Pharmaceuticals Ltd
Ad hoc announcement pursuant to Art. 53 LR CEO, Jean-Paul Clozel, to update on how Idorsia is being adapted for sustainable value creationThe company is focused on extending the cash runway beyond...
Idorsia presents at the J.P. Morgan Healthcare Conference – Adapting Idorsia for sustainable value creation
10 janv. 2024 01h00 HE
|
Idorsia Pharmaceuticals Ltd
Ad hoc announcement pursuant to Art. 53 LR CEO, Jean-Paul Clozel, to update on how Idorsia is being adapted for sustainable value creationThe company is focused on extending the cash runway beyond...
New Phase 3 data with aprocitentan for patients with resistant hypertension has been presented at the American Society of Nephrology Kidney Week 2023
03 nov. 2023 17h30 HE
|
Idorsia Pharmaceuticals Ltd
Allschwil, Switzerland – November 3, 2023 Idorsia Ltd (SIX: IDIA) announced today that further data for aprocitentan, Idorsia’s investigational dual endothelin receptor antagonist for the treatment...
New Phase 3 data with aprocitentan for patients with resistant hypertension has been presented at the American Society of Nephrology Kidney Week 2023
03 nov. 2023 17h30 HE
|
Idorsia Pharmaceuticals Ltd
Allschwil, Switzerland – November 3, 2023 Idorsia Ltd (SIX: IDIA) announced today that further data for aprocitentan, Idorsia’s investigational dual endothelin receptor antagonist for the treatment...
Idorsia gibt Finanzergebnisse für die ersten neun Monate 2023 bekannt – Anpassung des Unternehmens zur Schaffung von nachhaltigem Wert
24 oct. 2023 01h00 HE
|
Idorsia Pharmaceuticals Ltd
Ad-hoc-Mitteilung gemäss Art. 53 KR Allschwil, Schweiz – 24. Oktober 2023 Idorsia Ltd (SIX: IDIA) gab heute die Finanzergebnisse für die ersten neun Monate 2023 bekannt. Business Highlights ...
Idorsia announces financial results for the first nine months of 2023 – adapting the company to create sustainable value
24 oct. 2023 01h00 HE
|
Idorsia Pharmaceuticals Ltd
Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland – October 24, 2023 Idorsia Ltd (SIX: IDIA) today announced its financial results for the first nine months of 2023. Business...
Idorsia is committed to further the science of sleep with a symposium and poster presentations at World Sleep 2023
23 oct. 2023 01h00 HE
|
Idorsia Pharmaceuticals Ltd
Allschwil, Switzerland – October 23, 2023 Idorsia Ltd (SIX: IDIA) today announced that it is committed to further the science of sleep with a symposium and poster presentations at World Sleep 2023, a...
Idorsia is committed to further the science of sleep with a symposium and poster presentations at World Sleep 2023
23 oct. 2023 01h00 HE
|
Idorsia Pharmaceuticals Ltd
Allschwil, Switzerland – October 23, 2023 Idorsia Ltd (SIX: IDIA) today announced that it is committed to further the science of sleep with a symposium and poster presentations at World Sleep 2023, a...